Interstitial lung disease associated with gefitinib

Respiratory Medicine

Volumn 100, Issue 4, 2006, Pages 698-704

  Kataoka, Kensuke ^a   Taniguchi, Hiroyuki ^b   Hasegawa, Yoshinori ^a   Kondoh, Yasuhiro ^b   Kimura, Tomoki ^b   Nishiyama, Osamu ^b   Imaizumi, Kazuyoshi ^a   Kawabe, Tsutomu ^a   Kume, Hiroaki ^a   Shimokata, Kaoru ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOSEI GENERAL HOSPITAL   (Japan)

Author keywords

Bronchoalveolar lavage; Gefitinib; Interferon inducible protein 10; Interstitial lung disease; Non small cell lung cancer; Thymus and activation regulated chemokine

Indexed keywords

CARBOPLATIN; CORTICOSTEROID; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEFITINIB; GEMCITABINE; METHYLPREDNISOLONE; OXYGEN; PACLITAXEL; PREDNISOLONE;

ADULT; AGED; CASE REPORT; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; EMPHYSEMA; FIBEROPTIC BRONCHOSCOPY; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG INFILTRATE; LUNG LAVAGE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAINTENANCE DRUG DOSE; MALE; MEDICAL RECORD; OXYGEN THERAPY; PATHOGENESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TH1 CELL; THORAX RADIOGRAPHY;

EID: 33344475251     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.07.015     Document Type: Article

References (22)

1. R.S. Herbst A.M. Maddox M.L. Rothenberg et. al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: Results of a phase I trial J Clin Oncol 20 2002 3815-3825
2. M. Fukuoka S. Yano G. Giaccone et. al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer J Clin Oncol 21 2003 2237-2246
3. A.G. Pallis D. Mavroudis N. Androulakis et. al. ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program Lung Cancer 40 2003 301-307
4. T.J. Lynch D.W. Bell R. Sordella et. al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129-2139
5. J.G. Paez P.A. Janne J.C. Lee et. al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497-1500
6. J.D. Hainsworth M.G. Mainwaring M. Thomas et. al. Gefitinib in the treatment of advanced, refractory non-small-cell lung cancer: Results in 124 patients Clin Lung Cancer 4 2003 347-355
7. R. Ieki E. Saitoh M. Shibuya Acute lung injury as a possible adverse drug reaction related to gefitinib Eur Respir J 22 2003 179-181
8. A. Inoue Y. Saijo M. Maemondo et. al. Severe acute interstitial pneumonia and gefitinib Lancet 361 2003 137-139
9. I. Okamoto K. Fujii M. Matsumoto et. al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer Lung Cancer 40 2003 339-342
10. K. Hotta S. Harita A. Bessho et. al. Interstitial lung disease (ILD) during gefitinib treatment in Japanese patients with non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group Proc Am Soc Clin Oncol 24 2004 629 (abstr 7063)
11. T. Seto N. Yamamoto Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey Proc Am Soc Clin Oncol 24 2004 629 (abstr 7064)
12. ÅuAstrazeneca. In-house data; result and discussion document concerning the prospective investigation on Iressa Tablet 250 (Special Investigation). 2004.
13. M.G. Kris R.B. Natale R.S. Herbst et. al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial JAMA 290 2003 2149-2158
14. H. Suzuki K. Aoshiba N. Yokohori A. Nagai Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis Cancer Res 63 2003 5054-5059
15. A.B. Rice C.R. Moomaw D.L. Morgan J.C. Bonner Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats Am J Pathol 155 1999 213-221
16. S.G. Kallapur A.H. Jobe M. Ikegami C.J. Bachurski Increased IP-10 and MIG expression after intra-amniotic endotoxin in preterm lamb lung Am J Respir Crit Care Med 167 2003 779-786
17. M.P. Keane D.A. Arenberg J.P. Lynch et. al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis J Immunol 159 1997 1437-1443
18. F. Abdullah P. Ovadia G. Feuerstein et. al. The novel chemokine mob-1: involvement in adult respiratory distress syndrome Surgery 122 1997 303-312
19. T. Imai T. Yoshida M. Baba M. Nishimura M. Kakizaki O. Yoshie Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector J Biol Chem 271 1996 21514-21521
20. E. Miyazaki S. Nureki T. Fukami et. al. Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia Am J Respir Crit Care Med 165 2002 1125-1131
21. N.B. Elkind Z. Szentpetery A. Apati et. al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa Cancer Res 65 2005 1770-1777
22. F.A. de Jong S. Marsh R.H. Mathijssen et. al. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition Clin Cancer Res 10 2004 5889-5894